Zimbabwe has rejected a substantial US healthcare agreement worth $367m (£272m) spanning five years due to Washington's request for confidential data.
This rejection became public following a official document from December was disclosed, which showed President Emmerson Mnangagwa deemed the agreement was "unbalanced".
A government spokesman has since explained that the US was demanding access to biological samples for scientific study and profit but was not willing to share the benefits from any future treatments.
"We must now begin the challenging and unfortunate task of winding down our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had provided more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has called for continued negotiations to find a agreement acceptable to all parties so the country's critical HIV treatment initiative can proceed.
Broader Context
This development follows a similar case in neighbouring Kenya, where a court blocked a related health funding agreement following concerns were filed about the security of citizens' medical information.
Since returning to the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had managed aid for the US government, but Trump claimed its expenditure was "inefficient" and his government was seeking government-to-government agreements to boost openness and responsibility.
As per reports, Sixteen nations in Africa have to date agreed to similar agreements, constituting over $18.3bn in committed funds.
Specifics of the Rejected Agreement
This assistance for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million currently on antiretroviral therapy through American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, without any equivalent guarantee of access to any medical innovations – like new medicines or tests – that might be developed from that provided information," he stated.
"In essence, our nation would supply the raw materials for medical research without any certainty that the resulting innovations would be accessible to our citizens if a new health crisis emerge."
National Interest and Global Health
Mangwana further said that the American exit from the global health body and its push of one-on-one health agreements were undermining structures already established through the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework created to manage potential global health emergencies.
"This system is designed to ensure that when a nation contributes its samples, the resulting advantages – including medicines and cures – are shared equitably, not monopolised solely by those with the resources to create them."
The government's concerns regarding the US deal "are not meant as hostility towards the US," he added.
"We are open to further dialogue with our American counterparts on how future collaboration might be structured in a manner that respects the sovereignty and dignity of both nations."
Health Experts Reaction
A leading public health body expressed it understood the government's concerns, but suggested that negotiations must proceed since a large portion of the country's Aids initiatives depended on external financing.
"If technical issues exist, such as those relating to data governance or implementation frameworks, these can often be resolved via technical clarification and mutually agreed protections," it commented.
The situation highlights the complex challenges between accepting vital foreign assistance and protecting local interests in an ever more data-driven world.